In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

As biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug ...

In this video interview, Ron Lanton, partner, Lanton Law, talks FDA layoffs and their impact on inspections and clinical ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to ...

Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in ...

Randomization monitoring is a type of statistical/central monitoring, which ICH notes should be performed by appropriately ...